Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $51.60.
Several brokerages recently issued reports on TARS. Oppenheimer reaffirmed an “outperform” rating and set a $63.00 target price (up from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th.
Read Our Latest Research Report on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Stock Up 5.6 %
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.10. The business had revenue of $40.81 million during the quarter, compared to analyst estimates of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same period last year, the company earned ($1.17) EPS. Analysts predict that Tarsus Pharmaceuticals will post -3.71 earnings per share for the current year.
Institutional Trading of Tarsus Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TARS. Quest Partners LLC bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth approximately $61,000. Canada Pension Plan Investment Board bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares in the last quarter. Dark Forest Capital Management LP bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $202,000. Finally, Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals in the first quarter valued at approximately $223,000. 90.01% of the stock is owned by institutional investors.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Stories
- Five stocks we like better than Tarsus Pharmaceuticals
- Where Do I Find 52-Week Highs and Lows?
- California Resources Stock Could Be a Huge Long-Term Winner
- What Are Growth Stocks and Investing in Them
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Stock Dividend Cuts Happen Are You Ready?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.